Hopeful findings for the HIV positive in Africa

Good news for those attempting to extend antiretroviral treatment to the many millions of people with HIV in developing countries who need medicines but do not receive them.

An extensive study over six years in Uganda and Zimbabwe supported by the UK’s Medical Research Council in Africa suggests that up to a third more patients could be offered treatment, even given existing stretched domestic resources, thanks to a simple trade-off.

The Dart study, published in the latest issue of the Lancet, suggests that regular laboratory monitoring for toxic effects is costly and unnecessary, diverting funds that could instead be used to provide more drugs to patients at an earlier point in the development of the disease.

The researchers, led by Diana Gibb, argue CD4 testing, to measure the breakdown of the body’s immune response, should take place after two years’ treatment to determine whether to switch to more expensive “second-line” therapies.

Health and science blog (Archived)

This blog, part of the FT's health series, is a forum for readers interested in the science, policy, management, technology, business and delivery of healthcare.

This blog is no longer active but it remains open as an archive.

About our regular bloggers

Margaret McCartney is a Glasgow-based GP and FT Weekend columnist. She started writing for the Life and Arts section in 2005 and moved to the magazine in 2008. She also has her own blog: www.margaretmccartney.com/blog

Clive Cookson has been a science journalist for the whole of his working life. He joined the FT in 1987. Clive, the FT's science editor, picks out the research that everyone should know about. He also discusses key policy issues, from R&D funding to science education.

Andrew Jack is pharmaceuticals correspondent, covering the industry and public health issues. He has been a journalist with the FT for 19 years, based in London, Paris and Moscow